Skip to NavigationSkip to content

Johnson & Johnson

J&J latest pharma firm to volunteer pricing data

Johnson & Johnson released its pricing data, as promised, in February and it has simply revealed that its average price increases have been below the 10% mark annually for the last five years. It follows a similar path trodden by MSD, known as Merck in North America, in the release of a brief table of price increases but levelled against the ‘Net Price Change’ that factors in rebates and reimbursements.

Pfizer’s Remicade biosimilar displays similar efficacy

Pfizer and Celltrion have announced new data for their Remicade biosimilar, Inflectra, that shows that the drug is comparable in safety and efficacy, in a recent Phase 3 trial treating Crohn’s disease. Remicade was worth sales of $5.76 billion to Johnson & Johnson in 2015.

The March 2017 issue of Pharmafocus is now live!

The latest edition of Pharmafocus is available to read online now! From breakthroughs in antibiotic resistance R&D to gene editing in precision medicine, its a packed issue.

Integra bids $1.045 billion for J&J’s neurosurgery business

Integra, a medical technology company, have announced that it has made a binding offer to acquire Johnson & Johnson’s Codman Neurosurgery business in an offer worth $1.045 billion in cash. The deal will bring Codman’s portfolio of devices focused upon advanced hydrocephalus, neuro-critical care and operative neurosurgery.

Five most talked about mergers and acquisitions of 2016

Published on 27/01/17 at 12:55pm

2017 has kicked off with a bang – as Johnson & Johnson confirmed a $30 billion deal to takeover of Actelion, swiftly followed by Celgene announcing that it was poised to acquire Delinia in a $775 million deal. As a result, we thought we’d take a look at some of the largest deals of last year that changed the face of the pharmaceutical industry.

J&J finally seals $30 billion deal for Actelion

Johnson & Johnson has, as expected, wrapped up the deal to acquire Actelion in a deal worth $30 billion, working out at a deal of $280 a share. The deal excludes the R&D unit of Actelion, which will be spun out into a new publicly traded company, named R&D NewCO, under the leadership of Actelion founder and CEO Jean-Paul Clozel.

J&J to reveal drug price increases next month

Next month, Johnson & Johnson will reveal the average price increases of its prescription drugs in a move to increase its transparency with patients; the information due to be released by the company will include the list price and net price.

Actelion acquisition hokey-cokey continues with J&J returning to table

The Actelion takeover saga continues with Johnson & Johnson back in the game, and now re-entering into exclusive negotiations. Actelion had previously been engaged in discussion with Johnson & Johnson before negotiations broke off, with Sanofi entering into the arena.

J&J's largest India site to finally operate by 2018

Johnson & Johnson has reportedly announced that its manufacturing plant in Telangana, India, its largest site in the country, is due to be completed and fully operational by 2018, according to a top official knowledgeable on the matter.

Sanofi eyes Actelion merger as J&J backs down

After days of negotiations, Johnson and Johnson has stepped down from its attempts to acquire Swiss blood-pressure specialist Actelion, while Sanofi steps up to the plate with a reportedly larger valuation of the company.

Mission Statement is a leading portal for the pharmaceutical industry, providing industry professionals with pharma news, pharma events, pharma service company listings and pharma jobs,
Site content is produced by our editorial team exclusively for and our industry newspaper Pharmafocus. Service company profiles and listings are taken from our pharmaceutical industry directory, Pharmafile, and presented in a unique Find and Compare format to ensure the most relevant matches